This rule helps reduce risk of
infection due to communicable disease agents to blood product
recipients and to individuals handling blood products. This rule
allows the release of blood components prior to completion of
testing in documented medical emergencies and the shipment of blood
components for further manufacturing when the manufacturing process
necessitates rapid processing. The disclosure requirements help
ensure that personnel handling human blood or blood components with
reactive test results for evidence of infection due to communicable
disease agents are aware of this fact and can take
appropriate...
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.